Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

When somebody's coming in that has a known diagnosis of atopic dermatitis or eczema and things are really revved up still, if ...

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Any physical activity can be beneficial for eczema, as long as you’re choosing the right clothing and practicing good habits ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B ...

According to a recent meta-analysis published in eClinicalMedicine, antibiotic use during pregnancy or in early childhood ...

Doctors report a steady increase in eczema cases among infants across Indian cities. Experts warn that genetics and environmental factors are key drivers behind this troubling trend.

Certain pain-related pruritus descriptors may independently predict mental health outcomes, sleep disturbance, and QOL reduction in patients with AD.